ArticleAmerican journal of translational research2015
CDCA5 overexpression is an indicator of poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.World journal of urology · 2017Pooled it
- Berberine diminishes the malignant progression of non-small cell lung cancer cells by targeting CDCA5 and CCNA2.Journal of natural medicines · 2025Article
- CDCA5 promoted cell invasion and migration by activating TGF-β1 pathway in human ovarian cancer cells.Journal of ovarian research · 2024Article
- YAP-mediated mechanotransduction in urinary bladder remodeling: Based on RNA-seq and CUT&Tag.Frontiers in genetics · 2023Article
- CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker.Oncology reports · 2022Article
- Loss of cell division cycle‑associated 5 promotes cell apoptosis by activating DNA damage response in clear cell renal cell carcinoma.International journal of oncology · 2022Article
- Knockdown of CDCA5 suppresses malignant progression of breast cancer cells by regulating PDS5A.Molecular medicine reports · 2022Article
- Prognostic and Immunological Roles of Cell Cycle Regulator CDCA5 in Human Solid Tumors.International journal of general medicine · 2022Article
- CDCA1/2/3/5/7/8 as novel prognostic biomarkers and CDCA4/6 as potential targets for gastric cancer.Translational cancer research · 2021Article
- The roles of the cell division cycle-associated gene family in hepatocellular carcinoma.Journal of gastrointestinal oncology · 2021Article
- Data mining combined with experiments to validate CEP55 as a prognostic biomarker in colorectal cancer.Immunity, inflammation and disease · 2021Article
- A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.BMC cancer · 2021Article
- Identification and analysis of genes associated with epithelial ovarian cancer by integrated bioinformatics methods.PloS one · 2021Article
- Identifying and Validating Potential Biomarkers of Early Stage Lung Adenocarcinoma Diagnosis and Prognosis.Frontiers in oncology · 2021Article
- Article
- The role of theAnnals of translational medicine · 2020Article
- CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k/AKT/mTOR pathway activation.Journal of Cancer · 2020Article
- Knockdown of CDCA8 inhibits the proliferation and enhances the apoptosis of bladder cancer cells.PeerJ · 2020Article
- CDCA2 Inhibits Apoptosis and Promotes Cell Proliferation in Prostate Cancer and Is Directly Regulated by HIF-1α Pathway.Frontiers in oncology · 2020Article
- Bioinformatics Analysis Reveals Biomarkers With Cancer Stem Cell Characteristics in Lung Squamous Cell Carcinoma.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsUrothelial carcinoma (UC) is the most common tumor involving upper urinary tract (UTUC) and urinary bladder (UBUC) whose molecular survival determinants remains obscured. By computerizing a public transcriptomic database of UBUCs (GSE32894), we identified cell division cycle associated 5 (CDCA5) as the most significantly upregulated gene among those associated with G1-S transition of the mitotic cell cycle (GO:0000082). We therefore analyzed the clinicoptaological significance of CDCA5 expression in our well-characterized UC cohort. METHODS AND
resultsQuantigene assay was used to detect CDCA5 transcript levels in 36 UTUCs and 30 UBUCs. We used immunohistochemistry evaluated by H-scores to determine CDCA5 protein expression in 295 UBUCs and 340 UTUCs, respectively. CDCA5 expression was further correlated with clinicopathological features and disease-specific survival (DSS) and metastasis-free survival (MeFS). For both groups of UCs, increments of CDCA5 transcript levels were associated with higher pT status, CDCA5 protein overexpression was also significantly associated with advanced pT status, nodal metastasis, high histological grade, vascular invasion, and frequent mitoses. CDCA5 overexpression was predictive for worse DSS and MeFS in univariate and multivariate analysis.
conclusionsCDCA5 overexpression is associated with advanced clinical features of UC, suggesting its potential value as a prognostic biomarker and a novel therapeutic target.
Indexed as
Identifiers
26064439PMC4455346What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.